Dianthus Therapeutics Inc (DNTH)
26.00
-0.96
(-3.56%)
USD |
NASDAQ |
Jun 14, 16:00
25.94
-0.06
(-0.21%)
After-Hours: 20:00
Dianthus Therapeutics Enterprise Value: 386.05M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 386.05M |
| June 13, 2024 | 414.23M |
| June 12, 2024 | 361.40M |
| June 11, 2024 | 326.18M |
| June 10, 2024 | 252.95M |
| June 07, 2024 | 213.77M |
| June 06, 2024 | 237.25M |
| June 05, 2024 | 284.80M |
| June 04, 2024 | 261.02M |
| June 03, 2024 | 265.42M |
| May 31, 2024 | 257.21M |
| May 30, 2024 | 230.50M |
| May 29, 2024 | 273.35M |
| May 28, 2024 | 266.30M |
| May 24, 2024 | 284.80M |
| May 23, 2024 | 261.90M |
| May 22, 2024 | 299.47M |
| May 21, 2024 | 344.08M |
| May 20, 2024 | 370.20M |
| May 17, 2024 | 375.19M |
| May 16, 2024 | 393.39M |
| May 15, 2024 | 435.65M |
| May 14, 2024 | 442.99M |
| May 13, 2024 | 386.34M |
| May 10, 2024 | 335.86M |
| Date | Value |
|---|---|
| May 09, 2024 | 354.65M |
| May 08, 2024 | 321.78M |
| May 07, 2024 | 328.53M |
| May 06, 2024 | 325.00M |
| May 03, 2024 | 380.16M |
| May 02, 2024 | 327.62M |
| May 01, 2024 | 284.19M |
| April 30, 2024 | 249.56M |
| April 29, 2024 | 265.70M |
| April 26, 2024 | 253.96M |
| April 25, 2024 | 238.99M |
| April 24, 2024 | 248.68M |
| April 23, 2024 | 310.31M |
| April 22, 2024 | 305.03M |
| April 19, 2024 | 305.32M |
| April 18, 2024 | 316.47M |
| April 17, 2024 | 307.96M |
| April 16, 2024 | 331.44M |
| April 15, 2024 | 364.60M |
| April 12, 2024 | 382.80M |
| April 11, 2024 | 353.74M |
| April 10, 2024 | 292.70M |
| April 09, 2024 | 330.85M |
| April 08, 2024 | 315.00M |
| April 05, 2024 | 359.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-90.15M
Minimum
Dec 18 2023
763.62M
Maximum
Mar 22 2024
233.51M
Average
249.56M
Median
Apr 30 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.75M |
| Revenue (Quarterly) | 0.874M |
| Total Expenses (Quarterly) | 18.72M |
| EPS Diluted (Quarterly) | -0.54 |
| Profit Margin (Quarterly) | -1.57K% |
| Earnings Yield | -21.20% |
| Normalized Earnings Yield | -21.17 |